MX2019010484A - Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos. - Google Patents

Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.

Info

Publication number
MX2019010484A
MX2019010484A MX2019010484A MX2019010484A MX2019010484A MX 2019010484 A MX2019010484 A MX 2019010484A MX 2019010484 A MX2019010484 A MX 2019010484A MX 2019010484 A MX2019010484 A MX 2019010484A MX 2019010484 A MX2019010484 A MX 2019010484A
Authority
MX
Mexico
Prior art keywords
omega
vitamin
levels
individuals
identify
Prior art date
Application number
MX2019010484A
Other languages
English (en)
Spanish (es)
Inventor
BOWMAN Gene
Laure HUDRY-LABBE Julie
Antonius Johannes Schmitt Jeroen
Boschat Corina
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17193916.8A external-priority patent/EP3388061A1/en
Application filed by Nestle Sa filed Critical Nestle Sa
Priority claimed from PCT/EP2017/082148 external-priority patent/WO2018188771A1/en
Publication of MX2019010484A publication Critical patent/MX2019010484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2019010484A 2017-04-11 2017-12-11 Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos. MX2019010484A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762484156P 2017-04-11 2017-04-11
US201762484119P 2017-04-11 2017-04-11
EP17193916.8A EP3388061A1 (en) 2017-04-11 2017-09-29 Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
US201762580574P 2017-11-02 2017-11-02
PCT/EP2017/082148 WO2018188771A1 (en) 2017-04-11 2017-12-11 Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals

Publications (1)

Publication Number Publication Date
MX2019010484A true MX2019010484A (es) 2019-10-17

Family

ID=67682482

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010484A MX2019010484A (es) 2017-04-11 2017-12-11 Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.
MX2019010828A MX2019010828A (es) 2017-04-11 2018-04-05 Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019010828A MX2019010828A (es) 2017-04-11 2018-04-05 Metodos para identificar la predisposicion al declive cognitivo y agentes para reducir o prevenir el declive cognitivo o para mejorar la capacidad cognitiva.

Country Status (9)

Country Link
US (6) US20210128587A1 (https=)
EP (3) EP3609490A1 (https=)
JP (6) JP7270546B2 (https=)
CN (3) CN110381935A (https=)
AU (5) AU2017408873A1 (https=)
BR (3) BR112019017949A2 (https=)
CA (3) CA3054846A1 (https=)
ES (1) ES3056791T3 (https=)
MX (2) MX2019010484A (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381935A (zh) * 2017-04-11 2019-10-25 雀巢产品有限公司 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平
WO2018188771A1 (en) 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
CN113252806B (zh) * 2021-03-25 2023-08-29 嘉兴学院 S-腺苷同型半胱氨酸在制备用于诊断或治疗川崎病的产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
GB0016460D0 (en) * 2000-07-04 2000-08-23 Axis Shield Asa Assay
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US8017657B1 (en) * 2001-09-07 2011-09-13 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
CA2517290A1 (en) * 2003-02-26 2004-09-10 Kyowa Hakko Kogyo Co., Ltd. Muscle-building agent and preventive or remedy for muscle weakening
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
MX2010000224A (es) 2007-06-26 2010-05-03 Nutricia Nv Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
ES2664777T5 (es) * 2007-10-04 2021-10-25 Nestle Sa Composiciones y procedimientos para mejorar la función cognitiva
CA2994586C (en) * 2008-01-04 2020-07-21 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
NZ628281A (en) 2008-12-09 2016-05-27 Stephanie Fryar Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
JP2012513774A (ja) * 2008-12-31 2012-06-21 ニトロメガ コーポレーション ニトロ脂肪酸を含有する栄養補助物
CN101897706A (zh) * 2009-05-27 2010-12-01 北京奥萨医药研究中心有限公司 含有叶酸和b族维生素的组合物及其用途
EP2440201A1 (en) * 2009-06-10 2012-04-18 Energy4life Ag Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
US8563609B2 (en) * 2010-05-13 2013-10-22 Nitromega Corp. Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
EP2627326A2 (en) * 2010-10-12 2013-08-21 Vifor SA Novel omega-3 and omega-6 fatty acid compositions and uses thereof
JP2014515011A (ja) * 2011-03-18 2014-06-26 ネステク ソシエテ アノニム 加齢に伴う疾病を改善するのに有用な組成物及び方法
RU2014121888A (ru) * 2011-10-31 2015-12-10 Н.В. Нютрисиа Композиция для улучшения оценки батареи нейропсихологических тестов
AU2013299656C1 (en) * 2012-08-07 2017-06-22 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
FR3002044A1 (fr) * 2013-02-08 2014-08-15 Centre Nat Rech Scient Marqueur dyrk1a pour la maladie d'alzheimer
US20140271844A1 (en) * 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
AU2014235034A1 (en) 2013-03-15 2015-10-01 Buck Institute For Research On Aging Improved cognitive supplements
EP2899543A1 (en) 2014-01-28 2015-07-29 Predemtec GmbH Biomarker and methods for early diagnosis of Alzheimer's disease
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
ES2860427T3 (es) * 2015-06-22 2021-10-05 Nestle Sa Composiciones y métodos para mejorar la neurogénesis en animales
WO2017004436A2 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California A therapeutic system comprising pharmaceuticals in combination with metabolic enhancement for neurodegeneration
US20180268940A1 (en) * 2015-09-25 2018-09-20 Buck Institute For Research On Aging Compositions and methods for specific biological cognitive functions in neurodegenerative diseases
JP2019518744A (ja) * 2016-05-27 2019-07-04 ネステク ソシエテ アノニム 運動障害を治療又は予防するための栄養組成物
US11813233B2 (en) * 2016-09-29 2023-11-14 Societe Des Produits Nestle S.A. Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia
CN110381935A (zh) * 2017-04-11 2019-10-25 雀巢产品有限公司 用于识别和减轻个体的认知衰老的ω-3脂肪酸和维生素D水平

Also Published As

Publication number Publication date
EP3609491A2 (en) 2020-02-19
EP3609487B1 (en) 2026-03-18
JP2022166175A (ja) 2022-11-01
JP2020516586A (ja) 2020-06-11
BR112019018729A2 (pt) 2020-04-07
AU2018251092B2 (en) 2024-02-29
AU2018251094A1 (en) 2019-09-05
ES3056791T3 (en) 2026-02-24
CN110475553A (zh) 2019-11-19
US20200054665A1 (en) 2020-02-20
CN110381935A (zh) 2019-10-25
AU2018251092A1 (en) 2019-09-05
JP2020516864A (ja) 2020-06-11
JP7434458B2 (ja) 2024-02-20
JP7270547B2 (ja) 2023-05-10
EP3609487A1 (en) 2020-02-19
AU2024200882B9 (en) 2025-11-20
JP2023030130A (ja) 2023-03-07
JP2022172152A (ja) 2022-11-15
US20210128587A1 (en) 2021-05-06
AU2024200882A1 (en) 2024-02-29
US20210263048A1 (en) 2021-08-26
CA3054869A1 (en) 2018-10-18
US20230310488A1 (en) 2023-10-05
EP3609490A1 (en) 2020-02-19
CN110430873A (zh) 2019-11-08
CA3054864A1 (en) 2018-10-18
AU2018251094B2 (en) 2023-11-02
AU2024200882B2 (en) 2025-07-24
AU2025220690A1 (en) 2025-09-04
US20230028607A1 (en) 2023-01-26
JP7434459B2 (ja) 2024-02-20
JP2020516862A (ja) 2020-06-11
US20240041915A1 (en) 2024-02-08
JP7524294B2 (ja) 2024-07-29
EP3609491B1 (en) 2025-11-05
CA3054846A1 (en) 2018-10-18
BR112019020008A2 (pt) 2020-04-28
AU2017408873A1 (en) 2019-08-29
JP7270546B2 (ja) 2023-05-10
MX2019010828A (es) 2019-10-15
BR112019017949A2 (pt) 2020-05-19

Similar Documents

Publication Publication Date Title
EA201892489A1 (ru) Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma)
EA201792389A1 (ru) Пцр в реальном времени для мультиплексной оптимизированной амплификации с несоответствиями (moma) и для оценки неклеточной днк
EP4524255A3 (en) Methods and compositions for nucleic acid analysis
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
BR112016016831A8 (pt) método implementado por computador, sistema incluindo memória e um ou mais processadores, e meio legível por computador não transitório
EP3258270A4 (en) Cardiac troponin i ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor
ZA202003408B (en) A microcapsule for detecting and/or quantitating an analyte in a sample
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
PT110171A (pt) Método de treino da capacidade cognitiva com base emocional
CL2019000851A1 (es) Métodos para mejorar el resabio de bebidas alcohólicas usando alulosa.
MX2019010484A (es) Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.
EA201792538A1 (ru) Способ биологического получения метакриловой кислоты
BR112016006383A2 (pt) método de extração de proteína
MX376501B (es) Adn huésped como biomarcador de la enfermedad de crohn.
BR112016000231A8 (pt) métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos
BR112017013256A2 (pt) método de análise, portador de amostra em forma de disco e aplicação de um portador de amostra
PH12018502207A1 (en) Methods of manufacturing nutritional formulations
MX2015007494A (es) Metodo para diagnosticar leucodistrofia metacromatica.
WO2014207312A3 (en) Method of predicting risk for type 1 diabetes before seroconversion
MX2017010965A (es) Metodos de deteccion de listeria a partir de una muestra ambiental.
WO2016149386A8 (en) Biomarkers for malaria diagnosis
DK3638109T3 (da) Fremgangsmåde til bestemmelse af koncentrationen af en analyt i fuldblod
PL410179A1 (pl) Sposób otrzymywania erytrytolu
WO2018189020A3 (en) METHODS OF IDENTIFYING PREDISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR ENHANCING COGNITIVE CAPACITY